VACCINATION OF PATIENTS WITH ONCOLOGY DISEASES AGAINST MEASLES AND MUMPS

Cover Page

Cite item

Abstract

Abstract. One hundred and seven children (45 girls and 62 boys) in the age of 20 months — 14 years old (mean 9,62±0,37) suffered from acute lymphoblast leukosis and solid tumors in history have been examined in the clinic of Research Institute of children infections of FMBA. The vaccination history was studied in all children and the titers of specific antibodies to measles and mumps viruses as well as immune status were determined. 83,8% and 85,4% of studied children had no protection against measles and mumps respectively or had low titers of antibodies. Immunological examination of these children conducted within 4 months after finishing of therapy revealed absence of immunodeficiency. It gave opportunities to vaccinate or revaccinate these children against mentioned infections. Fifty three children were immunized against measles and 47 — against mumps. Application of live vaccines was safe because majority of vaccinated against measles (81,1%) and mumps (82,9%) children had mild vaccination process. It was established that to increase immunological efficacy of vaccination using of polyoxidony during 5 days before vaccination and 5 days after vaccination is reasonable.

About the authors

S. M. Kharit

ФГУ Научно-исследовательский институт детских инфекций ФМБА России, Санкт-Петербург

Author for correspondence.
Email: kharits-s@mail.ru

д.м.н., профессор, зав. отделом профилактики инфекционных болезней

197022, Санкт-Петербург, ул. Проф. Попова, 9

Russian Federation

T. V. Cherniaeva

ФГУ Научно-исследовательский институт детских инфекций ФМБА России, Санкт-Петербург

Email: kharits-s@mail.ru
Russian Federation

E. V. Cherniaeva

ФГУ Научно-исследовательский институт детских инфекций ФМБА России, Санкт-Петербург

Email: kharits-s@mail.ru
Russian Federation

N. K. Brusov

ФГУ Научно-исследовательский институт детских инфекций ФМБА России, Санкт-Петербург

Email: kharits-s@mail.ru
Russian Federation

References

  1. Костинов М.П. Вакцинация детей с нарушенным состоянием здоровья: Практическое руководство. — М., 2000. — 152 c.
  2. Парахонский А.П. Иммунный дисбаланс при опухолевых заболеваниях и его коррекция // Иммунитет и болезни: от теории к терапии: Материалы междунар. конгр. — М., 2005. — С. 187.
  3. Пинегин Б.В. Новые разработки на основе полиоксидония / Под ред. Б.В. Пинегина, И.Н. Царева. — М.: НПО Петровакс Фарм, 2004. — 24 с.
  4. Совершенствование организации специализирован ной помощи детям с онкогематологическими заболеваниями в Российской Федерации: Решение коллегии МЗ РФ; протокол № 3 от 19.02.2002.
  5. Avigan D., Pirofski L., Hillard M. Vaccination against infectious following hematopoietic stem cell transplantation // Biol. Blood. Marrow Transplant. — 2001. — N 7. — P. 171–183.
  6. Berkelhamer S., Borock E., Elsen C., Englund J., Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children / Clin. Infect. Dis. — 2001. — Vol. 32, N 7. — P. 1090–1094.
  7. Blythe T., Hahn T., Wall D., Camitta B. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (All) after first bone marrow or extramedullary relapse // Pediatr. Blood Cancer. — 2004. — Vol. 43, N 5. — P. 571–579.
  8. Emir S., Buyukpamukcu M., Koseoglu V., Hascelik G., Akyuz C., Kutluk T., Varan A. Varicella vaccination in children with lymphoma and solid tumours // Postgrad. Med. J. — 2006. — N 82. — P. 760–762.
  9. Gray M.M., Hann I.M., Glass S., Eden O.B., Jones P.M., Stevens R.F. Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centers: a retrospective review // Br. Med. J. (Clin. Res. Ed.). — 1987. — Vol. 295, N 6589. — P. 19–22.
  10. Molldrem J.J. Vaccination for Leukemia // Biol. Blood Marrow Transplant. — 2006. — Vol. 12, Iss. 1. (Supp. 1). — P. 13–18.
  11. Moritz B., Eder J., Meister B. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy // Med. Pediatr. Oncol. — 2001. — Vol. 36, N 2. — P. 283–289.
  12. Nilsson A., De Milito A., Engstrom P., Nordin M., Narita M., Grillner L. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antige // Pediatrics. — 2002. – Vol. 109, N 6. — e91.
  13. Okada H., Kobune F., Sato T.A. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients // Arch Virol. — 2000. — Vol. 145, N 5. — P. 905–920.
  14. Plotkin S.A., Orenstein W.A. Vaccines. — 4 ed. — USA: Elsevier one, 2004. — 1662 p.
  15. Torigoe S., Hirai S., Oitani K., Ito M., Ihara T., Iwasa T., Kamiya H., Sakurai M., Ueda S., Yamanishi K. Application of live attenuated measles and mumps vaccines in children with acute leukemia // Biken J. — 1981. — Vol. 24, N 4. — P. 147–151.
  16. Zignol M., Peracchi M., Tridello G., Pillon M., Fregonese F., D'Elia R., Zanesco L., Cesaro S. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer // Cancer. — 2004. — Vol. 101, N 3. — P. 635–641.

Copyright (c) 2014 Kharit S.M., Cherniaeva T.V., Cherniaeva E.V., Brusov N.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies